Peptic Ulcer Disease

Peptic ulcer disease (PUD) is a common and clinically significant condition characterized by a breach in the lining of the stomach or duodenum. Understanding its pathophysiology and management is critical because it moves beyond the outdated notion of being solely a "stress disease" to a treatable and often curable condition rooted in specific etiologies. Mastery of PUD is essential for any clinician, as it encompasses diagnostic reasoning, targeted antibiotic therapy, and the management of potentially life-threatening complications.

Pathophysiology: The Imbalance of Mucosal Defense

At its core, peptic ulcer disease results from an imbalance between aggressive factors—primarily gastric acid and pepsin—and the stomach's defensive mucosal barrier. The gastric mucosa is not passive; it maintains a dynamic defense system through a layer of mucus and bicarbonate, tight junctions between epithelial cells, and rapid cellular repair. An ulcer forms when these defenses are compromised, allowing acid and digestive enzymes to damage the underlying tissue. This erosion creates a discrete, punched-out lesion that extends through the muscularis mucosae, distinguishing it from the more superficial damage of gastritis or erosion. This foundational concept explains why treatment is twofold: reducing aggressive factors and, when possible, enhancing mucosal defense.

The Primary Culprit: Helicobacter pylori Infection

A monumental shift in our understanding of PUD came with the discovery of Helicobacter pylori, a gram-negative, spiral-shaped bacterium that colonizes the gastric mucosa. It is the leading cause of duodenal ulcers and a major cause of gastric ulcers globally. H. pylori does not simply exist in the stomach; it actively disrupts the mucosal defense. The bacterium produces urease, which hydrolyzes urea to ammonia, creating a protective alkaline cloud. More critically, it triggers a local inflammatory response and can directly damage epithelial cells, weakening the mucosal barrier and making it susceptible to acid. Not all infected individuals develop ulcers, but eradication of the infection dramatically reduces ulcer recurrence rates, proving its causative role.

Pharmacological Insult: NSAID-Induced Ulcers

The other major cause of PUD is the use of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, and aspirin. NSAIDs cause ulcers through a dual mechanism. Systemically, they inhibit cyclooxygenase-1 (COX-1), an enzyme critical for producing prostaglandins that maintain mucosal blood flow, stimulate mucus secretion, and promote bicarbonate production. Locally, the acidic nature of many NSAIDs can cause direct cellular injury. NSAID-induced ulcers require a different therapeutic approach, focusing on removing the offending agent and providing potent acid suppression to facilitate healing, rather than antibiotic therapy.

Diagnostic Confirmation and Assessing Complications

While a clinical history can be suggestive, definitive diagnosis and, crucially, assessment for complications typically require endoscopy (esophagogastroduodenoscopy, or EGD). During endoscopy, a gastroenterologist can directly visualize the ulcer, assess its characteristics, and obtain biopsies. Biopsies are vital to test for H. pylori infection via rapid urease test, histology, or culture, and to rule out malignancy in gastric ulcers. Furthermore, endoscopy is the primary tool for identifying and often treating complications. It can directly visualize and treat bleeding ulcers with techniques like injection, thermal coagulation, or clipping. It can identify signs of impending perforation or diagnose gastric outlet obstruction caused by scarring and edema from a chronic ulcer near the pylorus.

Targeted Treatment Protocols

Treatment is etiology-specific and is one of the most satisfying applications of medical knowledge, as it leads to cure.

For H. pylori-positive ulcers, the goal is eradication. The cornerstone of therapy is triple therapy, which combines a proton pump inhibitor (PPI) (e.g., omeprazole) with two antibiotics: clarithromycin and amoxicillin. The PPI raises the gastric pH, enhancing the effectiveness of the antibiotics and providing immediate symptom relief and ulcer healing. A typical regimen lasts 10-14 days. Due to rising clarithromycin resistance, alternative regimens like quadruple therapy (PPI, bismuth, metronidazole, tetracycline) are important fallback options. Eradication should always be confirmed with a follow-up test, such as a urea breath test, 4-6 weeks after completing therapy.

For NSAID-induced ulcers, the first step is to discontinue the NSAID if medically possible. Concurrently, high-dose PPI therapy is initiated to aggressively suppress acid and promote healing. If NSAID use must continue (e.g., for cardiovascular protection with aspirin), the patient must be placed on a gastroprotective agent like a PPI indefinitely. The COX-2 selective inhibitors (coxibs) are associated with a lower risk of ulcer formation but carry their own cardiovascular risks and are not a perfect solution.

Common Pitfalls

1. Treating Symptoms Without Confirming Etiology: Prescribing a PPI alone for a young patient with dyspepsia provides relief but misses the opportunity to cure an H. pylori infection. Always test for H. pylori in the context of an ulcer. Empiric treatment without confirmation can also lead to antibiotic resistance.
2. Incomplete Eradication of H. pylori: The most common reason for treatment failure is patient non-adherence to the multi-drug regimen. Stress the importance of completing the full course. Using a regimen with poor local efficacy rates (due to high antibiotic resistance) is another pitfall. Know your local resistance patterns.
3. Failing to Address NSAID Use: Simply adding a PPI while a patient continues to take high-dose NSAIDs is a setup for treatment failure or complication. A careful medication history, including over-the-counter use, is mandatory. Explore safer analgesic alternatives like acetaminophen.
4. Missing Alarm Features: Not recognizing symptoms that warrant urgent endoscopy—such as gastrointestinal bleeding, unexplained weight loss, anemia, early satiety, or persistent vomiting—can delay the diagnosis of a complicated ulcer or gastric cancer. These "red flag" symptoms should prompt immediate referral for endoscopy.

Summary

• Peptic ulcer disease is fundamentally caused by an imbalance between acid-pepsin aggression and mucosal defense, primarily driven by Helicobacter pylori infection or NSAID use.
• Definitive diagnosis and management of complications like bleeding, perforation, and gastric outlet obstruction are achieved through endoscopy.
• First-line treatment for H. pylori is triple therapy combining a proton pump inhibitor with clarithromycin and amoxicillin for 10-14 days, with eradication confirmation required.
• Management of NSAID-induced ulcers mandates discontinuation of the offending drug (if possible) and initiation of high-dose PPI therapy to promote healing.
• Always obtain a thorough medication history, test for H. pylori when an ulcer is diagnosed, and recognize "alarm symptoms" that necessitate urgent endoscopic evaluation.